Nasus Pharma (NSRX) Financial Ratios

For fiscal 2025 (fiscal year ended Dec 31, 2025), Nasus Pharma had debt-to-equity of 0.04 (up from -0.56), a current ratio of 2.25 (up from 0.12) and return on assets of -107.1% (up from -116.1%). A current ratio of 2.25 means current assets exceed current liabilities.

Nasus Pharma Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Income Statement Balance Sheet Cash Flow Ratios

Scroll to see more

Breakdown	FY 2025	FY 2024	FY 2023	FY 2022
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022
Valuation Ratios
P/B Ratio	29.95	-	-	-
Price/Tangible Book	29.95	-	-	-
Enterprise Value Ratios
Profitability & Returns
Return on Assets (ROA)	-107.15%	-116.06%	-166.52%	-
Return on Capital Employed (ROCE)	-172.60%	33.60%	30.20%	73.30%
Leverage & Solvency Ratios
Debt/Equity	0.04	-0.56	-0.65	-0.56
Liquidity Ratios
Current Ratio	2.25	0.12	0.10	0.13
Quick Ratio	1.98	0.07	0.05	0.05
Efficiency Ratios
Yield & Distribution Ratios
Earnings Yield	-7.06%	-	-	-
FCF Yield	-5.95%	-	-	-
Buyback Yield	-13.98%	0.43%	-2.44%	-

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Nasus Pharma Financial Ratios

What is Nasus Pharma's debt-to-equity ratio?

Nasus Pharma's debt-to-equity ratio was 0.04 for fiscal 2025 (period ended Dec 31, 2025). It was -0.56 a year earlier.

What is return on equity (ROE)?

Return on equity is net income divided by shareholders' equity. It measures how much profit a company generates from the capital its shareholders have invested. Full definition